[HTML] springer.com

[HTML][HTML] Galcanezumab provides consistent efficacy throughout the dosing interval among patients with episodic and chronic migraine: a post hoc analysis

P Pozo-Rosich, KH Samaan, TJ Schwedt… - Advances in …, 2021 - Springer
Introduction The consistency of the treatment effect of galcanezumab throughout the dosing
interval is examined in patients with episodic and chronic migraine. Methods This study was …
被引用次数：9 相关文章

Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis.

P Pozo-Rosich, KH Samaan, TJ Schwedt… - Advances in …, 2021 - europepmc.org
Methods This study was a post hoc analysis of clinical trial data from episodic (EVOLVE-1;
EVOLVE-2; both 6-month duration) and chronic (REGAIN; 3-month duration) migraine …

Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis

P Pozo-Rosich, KH Samaan… - Advances in …, 2021 - mayoclinic.elsevierpure.com
Introduction: The consistency of the treatment effect of galcanezumab throughout the dosing
interval is examined in patients with episodic and chronic migraine. Methods: This study was …

Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis

P Pozo-Rosich, KH Samaan, TJ Schwedt… - Advances in …, 2021 - ddd.uab.cat
The consistency of the treatment effect of galcanezumab throughout the dosing interval is
examined in patients with episodic and chronic migraine. This study was a post hoc analysis …
[HTML] nih.gov

[HTML][HTML] Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis

P Pozo-Rosich, KH Samaan, TJ Schwedt… - Advances in …, 2021 - ncbi.nlm.nih.gov
Methods This study was a post hoc analysis of clinical trial data from episodic (EVOLVE-1;
EVOLVE-2; both 6-month duration) and chronic (REGAIN; 3-month duration) migraine …

Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis

P Pozo-Rosich, KH Samaan, TJ Schwedt… - 2021 - pubmed.ncbi.nlm.nih.gov
Introduction The consistency of the treatment effect of galcanezumab throughout the dosing
interval is examined in patients with episodic and chronic migraine. Methods This study was …